Published in Med Care on August 01, 2002
Projections of the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst (2011) 10.29
Intensity-modulated radiation therapy, proton therapy, or conformal radiation therapy and morbidity and disease control in localized prostate cancer. JAMA (2012) 5.90
Survival following primary androgen deprivation therapy among men with localized prostate cancer. JAMA (2008) 5.66
Outcomes of localized prostate cancer following conservative management. JAMA (2009) 5.57
Cost implications of the rapid adoption of newer technologies for treating prostate cancer. J Clin Oncol (2011) 4.60
Evaluation of trends in the cost of initial cancer treatment. J Natl Cancer Inst (2008) 4.53
Long-term survival following partial vs radical nephrectomy among older patients with early-stage kidney cancer. JAMA (2012) 4.30
Complications following colonoscopy with anesthesia assistance: a population-based analysis. JAMA Intern Med (2013) 4.07
Use of surveillance for hepatocellular carcinoma among patients with cirrhosis in the United States. Hepatology (2010) 3.98
Risk profiles and treatment patterns among men diagnosed as having prostate cancer and a prostate-specific antigen level below 4.0 ng/ml. Arch Intern Med (2010) 3.85
Effect of adjuvant chemotherapy on survival of patients with stage III colon cancer diagnosed after age 75 years. J Clin Oncol (2012) 3.63
Linking inpatient clinical registry data to Medicare claims data using indirect identifiers. Am Heart J (2009) 3.57
Comparative effectiveness of prostate cancer treatments: evaluating statistical adjustments for confounding in observational data. J Natl Cancer Inst (2010) 3.24
Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-Medicare database. Hepatology (2011) 3.24
Adjuvant chemotherapy for stage II colon cancer with poor prognostic features. J Clin Oncol (2011) 3.22
Comparative effectiveness of prostate cancer surgical treatments: a population based analysis of postoperative outcomes. J Urol (2010) 3.18
Completion of therapy by Medicare patients with stage III colon cancer. J Natl Cancer Inst (2006) 3.18
Effectiveness of primary androgen-deprivation therapy for clinically localized prostate cancer. J Clin Oncol (2014) 3.17
Determinants of androgen deprivation therapy use for prostate cancer: role of the urologist. J Natl Cancer Inst (2006) 3.10
Assessing the impact of a cooperative group trial on breast cancer care in the medicare population. J Clin Oncol (2012) 3.07
Hospital volume and late survival after cancer surgery. Ann Surg (2007) 2.93
Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study. Gut (2005) 2.90
Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based case-control study. Clin Gastroenterol Hepatol (2007) 2.90
Population-attributable fractions of risk factors for hepatocellular carcinoma in the United States. Am J Gastroenterol (2013) 2.89
Contemporary risk profile of prostate cancer in the United States. J Natl Cancer Inst (2009) 2.85
Late gastrointestinal toxicities following radiation therapy for prostate cancer. Eur Urol (2011) 2.69
Effectiveness of bevacizumab with first-line combination chemotherapy for Medicare patients with stage IV colorectal cancer. J Clin Oncol (2012) 2.59
Carboplatin and paclitaxel with vs without bevacizumab in older patients with advanced non-small cell lung cancer. JAMA (2012) 2.56
Mortality by stage for right- versus left-sided colon cancer: analysis of surveillance, epidemiology, and end results--Medicare data. J Clin Oncol (2011) 2.43
Diffusion of surgical innovation among patients with kidney cancer. Cancer (2008) 2.38
Use of radiation therapy in the last 30 days of life among a large population-based cohort of elderly patients in the United States. J Clin Oncol (2012) 2.38
A most stubborn bias: no adjustment method fully resolves confounding by indication in observational studies. J Clin Epidemiol (2009) 2.33
Comparison of survival outcomes among cancer patients treated in and out of clinical trials. J Natl Cancer Inst (2014) 2.30
Urologist compliance with AUA best practice guidelines for benign prostatic hyperplasia in Medicare population. Urology (2011) 2.26
Racial and ethnic differences in breast cancer survival: how much is explained by screening, tumor severity, biology, treatment, comorbidities, and demographics? Cancer (2008) 2.23
Representativeness of participants in the cancer care outcomes research and surveillance consortium relative to the surveillance, epidemiology, and end results program. Med Care (2013) 2.22
Incidence of suicide in persons with cancer. J Clin Oncol (2008) 2.21
Primary care utilization and colorectal cancer outcomes among Medicare beneficiaries. Arch Intern Med (2011) 2.21
Risk of incisional hernia after minimally invasive and open radical prostatectomy. J Urol (2013) 2.18
Comparative effectiveness of 5 treatment strategies for early-stage non-small cell lung cancer in the elderly. Int J Radiat Oncol Biol Phys (2012) 2.17
End-of-life care for lung cancer patients in the United States and Ontario. J Natl Cancer Inst (2011) 2.14
Cardiovascular disease competes with breast cancer as the leading cause of death for older females diagnosed with breast cancer: a retrospective cohort study. Breast Cancer Res (2011) 2.13
Fracture after androgen deprivation therapy among men with a high baseline risk of skeletal complications. BJU Int (2013) 2.10
Explaining black-white differences in receipt of recommended colon cancer treatment. J Natl Cancer Inst (2005) 2.08
Tradeoffs between accuracy measures for electronic health care data algorithms. J Clin Epidemiol (2011) 2.06
Considerations for observational research using large data sets in radiation oncology. Int J Radiat Oncol Biol Phys (2014) 2.06
Readmission after lung cancer resection is associated with a 6-fold increase in 90-day postoperative mortality. J Thorac Cardiovasc Surg (2014) 2.04
Influence of patient, physician, and hospital factors on 30-day readmission following pancreatoduodenectomy in the United States. JAMA Surg (2013) 2.03
Racial disparities among patients with lung cancer who were recommended operative therapy. Arch Surg (2009) 2.02
Hospital factors and racial disparities in mortality after surgery for breast and colon cancer. J Clin Oncol (2009) 2.02
Incidence of the myelodysplastic syndromes using a novel claims-based algorithm: high number of uncaptured cases by cancer registries. Blood (2011) 2.02
Use, complications, and costs of stereotactic body radiotherapy for localized prostate cancer. Cancer (2016) 2.02
Prevalence and predictors of interval colorectal cancers in medicare beneficiaries. Cancer (2011) 2.01
Readmission after colectomy for cancer predicts one-year mortality. Ann Surg (2010) 2.01
Population-based study of autoimmune conditions and the risk of specific lymphoid malignancies. Int J Cancer (2009) 2.01
The influence of comorbidities on overall survival among older women diagnosed with breast cancer. J Natl Cancer Inst (2011) 2.00
Race/ethnicity and the receipt of watchful waiting for the initial management of prostate cancer. J Gen Intern Med (2004) 1.97
Effect of depression on diagnosis, treatment, and survival of older women with breast cancer. J Am Geriatr Soc (2004) 1.93
Risks of myeloid malignancies in patients with autoimmune conditions. Br J Cancer (2009) 1.89
Recurrence of high-risk bladder cancer: a population-based analysis. Cancer (2013) 1.87
Lobectomy, sublobar resection, and stereotactic ablative radiotherapy for early-stage non-small cell lung cancers in the elderly. JAMA Surg (2014) 1.86
Management and Outcomes of Esophageal Perforation: A National Study of 2,564 Patients in England. Am J Gastroenterol (2015) 1.83
Cancer screening among patients with advanced cancer. JAMA (2010) 1.82
Survival for older patients with acute myeloid leukemia: a population-based study. Haematologica (2012) 1.81
Long term survival with thoracoscopic versus open lobectomy: propensity matched comparative analysis using SEER-Medicare database. BMJ (2014) 1.81
Characteristics of urologists predict the use of androgen deprivation therapy for prostate cancer. J Clin Oncol (2007) 1.79
Disparities in breast cancer treatment and survival for women with disabilities. Ann Intern Med (2006) 1.78
Trends in treatment of advanced epithelial ovarian cancer in the Medicare population. Gynecol Oncol (2011) 1.77
Effect of a dementia diagnosis on survival of older patients after a diagnosis of breast, colon, or prostate cancer: implications for cancer care. Arch Intern Med (2008) 1.76
Multi-modality mediastinal staging for lung cancer among medicare beneficiaries. J Thorac Oncol (2009) 1.76
The association of statin use after cancer diagnosis with survival in pancreatic cancer patients: a SEER-medicare analysis. PLoS One (2015) 1.76
Trends in end-of-life ICU use among older adults with advanced lung cancer. Chest (2007) 1.76
External validation of medicare claims for breast cancer chemotherapy compared with medical chart reviews. Med Care (2006) 1.74
Racial and ethnic differences in end-of-life care in fee-for-service Medicare beneficiaries with advanced cancer. J Am Geriatr Soc (2008) 1.74
Effectiveness of adjuvant chemotherapy for node-positive operable breast cancer in older women. J Gerontol A Biol Sci Med Sci (2005) 1.73
Assessing the impact of screening colonoscopy on mortality in the medicare population. J Gen Intern Med (2011) 1.73
Quality of care in patients with bladder cancer: a case report? Cancer (2011) 1.73
Trends in hospital volume and patterns of referral for women with gynecologic cancers. Obstet Gynecol (2013) 1.72
Regional variation in quality of prostate cancer care. J Urol (2013) 1.72
Continuity of care and intensive care unit use at the end of life. Arch Intern Med (2009) 1.70
An observational study of outcomes after initial infused therapy in Medicare patients diagnosed with chronic lymphocytic leukemia. Blood (2010) 1.67
Readmission after pancreatectomy for pancreatic cancer in Medicare patients. J Gastrointest Surg (2009) 1.66
Does comorbidity influence the risk of myocardial infarction or diabetes during androgen-deprivation therapy for prostate cancer? Eur Urol (2012) 1.64
Surgeon characteristics and long-term trends in the adoption of laparoscopic radical nephrectomy. J Urol (2011) 1.64
Management of patients with pancreatic adenocarcinoma: national trends in patient selection, operative management, and use of adjuvant therapy. J Am Coll Surg (2011) 1.64
Androgen deprivation and thromboembolic events in men with prostate cancer. Cancer (2011) 1.62
Risk of hospitalization according to chemotherapy regimen in early-stage breast cancer. J Clin Oncol (2014) 1.62
Comparison of approaches for estimating prevalence costs of care for cancer patients: what is the impact of data source? Med Care (2009) 1.62
Health services research and data linkages: issues, methods, and directions for the future. Health Serv Res (2010) 1.62
Use of androgen deprivation therapy for metastatic prostate cancer in older men. BJU Int (2008) 1.59
Use of surveillance, epidemiology, and end results-medicare data to conduct case-control studies of cancer among the US elderly. Am J Epidemiol (2011) 1.59
Hematopoietic malignancies associated with viral and alcoholic hepatitis. Cancer Epidemiol Biomarkers Prev (2008) 1.59
Gender disparities in hematuria evaluation and bladder cancer diagnosis: a population based analysis. J Urol (2014) 1.58
Comorbidities and survival in a large cohort of patients with newly diagnosed myelodysplastic syndromes. Leuk Res (2009) 1.57
Longitudinal, population-based study of racial/ethnic differences in colorectal cancer survival: impact of neighborhood socioeconomic status, treatment and comorbidity. BMC Cancer (2007) 1.57
Patterns of care for early stage bladder cancer. Cancer (2010) 1.57
Primary care physicians who treat blacks and whites. N Engl J Med (2004) 12.23
Patients' expectations about effects of chemotherapy for advanced cancer. N Engl J Med (2012) 10.93
Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst (2005) 8.36
Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol (2005) 8.08
Variations in morbidity after radical prostatectomy. N Engl J Med (2002) 7.26
American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol (2004) 7.16
American Society of Clinical Oncology guidance statement: the cost of cancer care. J Clin Oncol (2009) 6.77
Care patterns in Medicare and their implications for pay for performance. N Engl J Med (2007) 6.74
Patterns of colorectal cancer screening uptake among men and women in the United States. Cancer Epidemiol Biomarkers Prev (2006) 6.67
Patterns and predictors of colorectal cancer test use in the adult U.S. population. Cancer (2004) 6.41
The surgical learning curve for prostate cancer control after radical prostatectomy. J Natl Cancer Inst (2007) 6.12
Using navigators to improve care of underserved patients: current practices and approaches. Cancer (2005) 5.56
Resurrecting treatment histories of dead patients: a study design that should be laid to rest. JAMA (2004) 5.43
Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol (2010) 5.21
Utility of the SEER-Medicare data to identify chemotherapy use. Med Care (2002) 5.07
Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes. J Natl Cancer Inst (2009) 5.05
Estimating health care costs related to cancer treatment from SEER-Medicare data. Med Care (2002) 4.88
Screening for lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest (2013) 4.83
A refined comorbidity measurement algorithm for claims-based studies of breast, prostate, colorectal, and lung cancer patients. Ann Epidemiol (2007) 4.81
Are physicians doing too much colonoscopy? A national survey of colorectal surveillance after polypectomy. Ann Intern Med (2004) 4.49
The financial toxicity of cancer treatment: a pilot study assessing out-of-pocket expenses and the insured cancer patient's experience. Oncologist (2013) 4.33
Use of SEER-Medicare data for measuring cancer surgery. Med Care (2002) 4.27
Survival of blacks and whites after a cancer diagnosis. JAMA (2002) 4.27
How to build and interpret a nomogram for cancer prognosis. J Clin Oncol (2008) 4.24
Studying radiation therapy using SEER-Medicare-linked data. Med Care (2002) 4.13
Physician visits prior to treatment for clinically localized prostate cancer. Arch Intern Med (2010) 4.11
Religious coping and use of intensive life-prolonging care near death in patients with advanced cancer. JAMA (2009) 4.04
The effect of clustering of outcomes on the association of procedure volume and surgical outcomes. Ann Intern Med (2003) 4.01
Effects of pathologic stage on the learning curve for radical prostatectomy: evidence that recurrence in organ-confined cancer is largely related to inadequate surgical technique. Eur Urol (2008) 3.93
Missed opportunities: racial disparities in adjuvant breast cancer treatment. J Clin Oncol (2006) 3.83
NCCN Task Force Report: Oral chemotherapy. J Natl Compr Canc Netw (2008) 3.82
Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study. Lancet Oncol (2006) 3.75
Colorectal cancer test use from the 2005 National Health Interview Survey. Cancer Epidemiol Biomarkers Prev (2008) 3.64
Effect of adjuvant chemotherapy on survival of patients with stage III colon cancer diagnosed after age 75 years. J Clin Oncol (2012) 3.63
Long-term toxicity monitoring via electronic patient-reported outcomes in patients receiving chemotherapy. J Clin Oncol (2007) 3.60
When you look matters: the effect of assessment schedule on progression-free survival. J Natl Cancer Inst (2007) 3.60
Primary care physicians' links to other physicians through Medicare patients: the scope of care coordination. Ann Intern Med (2009) 3.59
Patient demographic and socioeconomic characteristics in the SEER-Medicare database applications and limitations. Med Care (2002) 3.57
Delivery of preventive services to older adults by primary care physicians. JAMA (2005) 3.53
Survival outcomes after radiation therapy for stage III non-small-cell lung cancer after adoption of computed tomography-based simulation. J Clin Oncol (2011) 3.53
Linking physician characteristics and medicare claims data: issues in data availability, quality, and measurement. Med Care (2002) 3.36
Adverse events after outpatient colonoscopy in the Medicare population. Ann Intern Med (2009) 3.34
Patient online self-reporting of toxicity symptoms during chemotherapy. J Clin Oncol (2005) 3.29
Health plan policies and programs for colorectal cancer screening: a national profile. Am J Manag Care (2004) 3.27
Effect of surgeon specialty on processes of care and outcomes for ovarian cancer patients. J Natl Cancer Inst (2006) 3.19
Cost consequences of the 340B drug discount program. JAMA (2013) 3.17
Rapid-learning system for cancer care. J Clin Oncol (2010) 3.13
Differences between primary care physicians' and oncologists' knowledge, attitudes and practices regarding the care of cancer survivors. J Gen Intern Med (2011) 3.11
Association of hospital procedure volume and outcomes in patients with colon cancer at high risk for recurrence. Ann Intern Med (2003) 3.01
A national survey of primary care physicians' methods for screening for fecal occult blood. Ann Intern Med (2005) 3.01
A paradigm shift in U.S. Breast reconstruction: increasing implant rates. Plast Reconstr Surg (2013) 3.00
Adjuvant chemotherapy use and adverse events among older patients with stage III colon cancer. JAMA (2010) 2.93
Palliative radiation therapy practice in patients with metastatic non-small-cell lung cancer: a Cancer Care Outcomes Research and Surveillance Consortium (CanCORS) Study. J Clin Oncol (2013) 2.91
State expenditures for tobacco-control programs and the tobacco settlement. N Engl J Med (2002) 2.81
Hospital and surgeon procedure volume as predictors of outcome following rectal cancer resection. Ann Surg (2002) 2.71
American Society of Clinical Oncology/National Comprehensive Cancer Network Quality Measures. J Clin Oncol (2008) 2.69
How Medicare could use comparative effectiveness research in deciding on new coverage and reimbursement. Health Aff (Millwood) (2010) 2.68
Adjuvant chemotherapy for stage III colon cancer: do physicians agree about the importance of patient age and comorbidity? J Clin Oncol (2008) 2.62
Effectiveness of bevacizumab with first-line combination chemotherapy for Medicare patients with stage IV colorectal cancer. J Clin Oncol (2012) 2.59
Current capacity for endoscopic colorectal cancer screening in the United States: data from the National Cancer Institute Survey of Colorectal Cancer Screening Practices. Am J Med (2003) 2.56
Carboplatin and paclitaxel with vs without bevacizumab in older patients with advanced non-small cell lung cancer. JAMA (2012) 2.56
In search of the perfect comorbidity measure for use with administrative claims data: does it exist? Med Care (2006) 2.53
American Society of Clinical Oncology 2009 clinical evidence review on radiofrequency ablation of hepatic metastases from colorectal cancer. J Clin Oncol (2009) 2.52
Delivering high-quality and affordable care throughout the cancer care continuum. J Clin Oncol (2013) 2.39
Federal initiatives to support rapid learning about new technologies. Health Aff (Millwood) (2007) 2.36
Adjuvant chemotherapy and survival in older women with hormone receptor-negative breast cancer: assessing outcome in a population-based, observational cohort. J Clin Oncol (2006) 2.32
Barriers to breast and colorectal cancer survivorship care: perceptions of primary care physicians and medical oncologists in the United States. J Clin Oncol (2013) 2.32
Patterns of colorectal cancer test use, including CT colonography, in the 2010 National Health Interview Survey. Cancer Epidemiol Biomarkers Prev (2012) 2.31
Survivorship care plans in research and practice. CA Cancer J Clin (2012) 2.31
Cancer, comorbidities, and health-related quality of life of older adults. Health Care Financ Rev (2008) 2.20
Prevalence of off-label use and spending in 2010 among patent-protected chemotherapies in a population-based cohort of medical oncologists. J Clin Oncol (2013) 2.20
Patterns of recurrence and second primary lung cancer in early-stage lung cancer survivors followed with routine computed tomography surveillance. J Thorac Cardiovasc Surg (2012) 2.08
Measuring complications of cancer treatment using the SEER-Medicare data. Med Care (2002) 2.05
Desire for information and involvement in treatment decisions: elderly cancer patients' preferences and their physicians' perceptions. J Clin Oncol (2007) 2.04
Data sources for measuring colorectal endoscopy use among Medicare enrollees. Cancer Epidemiol Biomarkers Prev (2007) 2.02
Health care provider surveys in the United States, 2000-2010: a review. Eval Health Prof (2013) 2.02
Rapidity and modality of imaging for acute low back pain in elderly patients. Arch Intern Med (2009) 2.01
Race/ethnicity and the receipt of watchful waiting for the initial management of prostate cancer. J Gen Intern Med (2004) 1.97
The impact of complications on outcomes after resection for esophageal and gastroesophageal junction carcinoma. J Am Coll Surg (2004) 1.97
Use of information resources by patients with cancer and their companions. Cancer (2004) 1.93
Cancer's next frontier: addressing high and increasing costs. JAMA (2010) 1.93
Adjuvant chemotherapy use for Medicare beneficiaries with stage II colon cancer. J Clin Oncol (2002) 1.93
Evaluation of an online platform for cancer patient self-reporting of chemotherapy toxicities. J Am Med Inform Assoc (2007) 1.89
The effect of changes in tumor size on breast carcinoma survival in the U.S.: 1975-1999. Cancer (2005) 1.86
Physician use of genetic testing for cancer susceptibility: results of a national survey. Cancer Epidemiol Biomarkers Prev (2003) 1.83
Cancer screening among patients with advanced cancer. JAMA (2010) 1.82
Comparison of approaches for estimating incidence costs of care for colorectal cancer patients. Med Care (2009) 1.76
Patterns of adjuvant chemotherapy use in a population-based cohort of patients with resected stage II or III colon cancer. J Clin Oncol (2011) 1.75
Use of surgery among elderly patients with stage IV colorectal cancer. J Clin Oncol (2004) 1.74
Surgeon volume compared to hospital volume as a predictor of outcome following primary colon cancer resection. J Surg Oncol (2003) 1.73
Colorectal cancer screening barriers and facilitators in older persons. Prev Med (2009) 1.73
Cancer screening test use - United States, 2013. MMWR Morb Mortal Wkly Rep (2015) 1.72